Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients.

ABSTRACT: A proof-of-concept study was conducted to assess whether patients with advanced stage IV cancer for whom predominantly no standard therapy was available could benefit from comprehensive molecular profiling of their tumor tissue to provide targeted therapy. Tumor samples of 83 patients were collected under highly standardized conditions and analyzed using immunohistochemistry, next-generation sequencing and phosphoprotein profiling. Expression and phosphorylation of key oncogenic pathways were measured to identify targets at the (phospho-) proteomic level. At genomic level, 50 oncogenes and tumor suppressor genes were analyzed. Based on molecular profiling, targeted therapies were decided by the attending oncologist. Accordingly, 28 patients who met the defined criteria fell in two equal-si

SUBMITTER: Samsen A 

PROVIDER: S-EPMC6205171 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature